Sodium oxybate in the treatment of binge eating disorder: an open-label, prospective study.
OBJECTIVE
To assess preliminarily the effectiveness of sodium oxybate in binge eating disorder.


METHODS
This was an open-label, prospective, 16-week, flexible dose study of sodium oxybate in binge eating disorder. The primary outcome was binge eating episode frequency.


RESULTS
Twelve individuals received sodium oxybate, 10 completed at least one postbaseline evaluation, and five completed the study. Mean dose at endpoint was 7.1 (2.0) g/day. Sodium oxybate was associated with significant reductions in frequency of binge days and binge episodes, as well as measures of clinical severity, eating pathology, obsessive-compulsive symptoms, food cravings, body mass index, and body weight. Nine participants had remission of binge eating and five lost ≥5% of their baseline weight; all five of the latter participants had remission of binge eating.


CONCLUSIONS
In this open-label trial, sodium oxybate was effective in binge eating disorder, but associated with high a discontinuation rate.
McElroy
Susan L
SL
Research Institute, Lindner Center of HOPE, Mason, Ohio, USA.
Guerdjikova
Anna I
AI
Winstanley
Erin L
EL
O'Melia
Anne M
AM
Mori
Nicole
N
Keck
Paul E
PE
Hudson
James I
JI
D000328:Adult; D056912:Binge-Eating Disorder / Q000188:drug therapy*; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D012720:Severity of Illness Index; D012978:Sodium Oxybate / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D012978:Sodium Oxybate